The Lynx Group

Phoebe Starr


Authored Items

Venetoclax plus Rituximab New Chemotherapy-Free Option for Chronic Lymphocytic Leukemia

Leukemia, Web Exclusives

Atlanta, GA—Venetoclax (Venclexta) plus rituximab (Rituxan) achieved superior progression-free survival (PFS) and overall survival (OS) compared with standard-of-care bendamustine (Treanda/Bendeka) plus rituximab in patients with relapsed or refractory chronic lymphocytic leukemia (CLL). PFS improved by 81% and OS by 52% with venetoclax plus rituximab, and the depth of response was [ Read More ]

SNPs Identified for Further Study in Association With QOL in Men With Prostate Cancer Treated With Radiation

April 2013, Vol 2, No 2 - Uncategorized

Investigators at Harvard Medical School have identified candidate single nucleotide polymorphisms (SNPs) in genes associated with inflammation that will be explored further with regard to their associations with long-term quality-of-life (QOL) effects of radiation therapy (RT) in men with prostate cancer. The authors found 7 SNPs significantly associated with long-term [ Read More ]

Stereotactic Body Radiation Therapy Is Effective, Cost Saving, and Convenient for Patients With Prostate Cancer

December 2012, Vol 1, No 6 - Uncategorized

In the United States right now, intensity-modulated radiation therapy (IMRT) has largely replaced 3-D conformal radiation therapy as the technique of choice for most patients with organ-confined prostate cancer treated with radiation as primary therapy. Other techniques in use include brachytherapy, and at some centers proton beam therapy is being [ Read More ]

Ibrutinib: Proof of Concept Pays Off

December 2012, Vol 1, No 6 - Uncategorized

Ibrutinib as a single agent and in combination with ri­tuximab achieved unprecedented response rates in studies of chronic lymphocytic leukemia (CLL) and mantle cell lymphoma (MCL) presented at the 54th Annual Meeting of the American Society of Hematology (ASH). The drug is being studied in several B-cell malignancies, including CLL/small [ Read More ]

Crizotinib Extends Survival Versus Chemotherapy in Advanced NSCLC

November 2012, Vol 1, No 5 - Uncategorized

The PROFILE 1007 trial, reported at the 2012 ESMO Congress, showed positive results for a targeted therapy in patients whose tumors expressed that target. The first-in-class ALK inhibitor crizotinib prolonged progression-free survival (PFS) and improved response rates compared with single-agent chemotherapy in patients with advanced, previously treated, ALK-positive (ALK+), non–small [ Read More ]

Sign me up!